New endocrine therapy for patients with scirrhous type gastric cancer using LH-RH analogue (Zoladex)

为了改善硬化型胃癌患者的预后，我们研究了应用促黄体激素释放激素类似物(左来得)进行内分泌治疗的新方法。1.对癌细胞株的抑制作用研究结果发现，1×10^-6&gt；-7&gt；-1×10^&lt；-6&gt；-7&gt；M与E_2合用对雌激素受体阳性的Kato-III细胞的增殖有抑制作用，而对雌激素受体阴性的KKOI细胞的增殖无抑制作用。在硬化型胃癌患者中，服用唑拉得后，血清雌激素水平下降。然而，目前尚不清楚佐拉德克斯是否能缩小硬化型胃癌的体积。在本研究中，佐拉德克斯可能用于治疗硬化型胃癌。

In order to improving prognosis of scirrhous type gastric cancer patients, we studied new endocrine therapy using LH-RH analogue (Zoladex). 1. Studies on inhibition of cancer cell line. It was found that the proliferation of the KATO-III cell line (estrogenreceptor-positivecell) was inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. On the other hand, the proliferation of MKOI (ER negative cell) was not inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. In nude mouse bearing xenograft tumor, Kato-III cells were inhibited by Zoladex. In patients with scirrhous-type gastric cancer, the levels of serum estrogen decreased after administration of Zoladex. However, it was not clear that the size of scirrhous-type gastric cancer decreased by Zoladex. In the present study, it can be concluded that Zoladex might be useful for the treatment of scirrhous-type gastric cacer.